The pace of change in drug discovery and clinical development has been unmatched in recent years, with technologies such as AI accelerating these processes.
As the US and Europe experiences shortages of crucial medicines, Ben Hargreaves looks at how a once thriving generics industry is now struggling, with many companies seeking to exit the spa
South Korean contract development and manufacturing organisation (CDMO) Samsung Biologics marks another contract milestone as the company announces two high-value deals totalling £897